DoD Tick-Borne Disease, Idea Development Award | W81XWH 21 TBDRP IDA

Opportunity Information: Apply for W81XWH 21 TBDRP IDA

The Department of Defense Tick-Borne Disease Research Program (TBDRP) Idea Development Award (FY21) is designed to fund highly innovative research projects that can drive meaningful progress in Lyme disease and other tick-borne diseases. The main aim is to generate impactful discoveries or major advancements that improve research direction, patient care, and overall quality of life, with particular relevance to military Service Members, Veterans, and their beneficiaries, while also benefiting the broader U.S. public. The opportunity is explicitly geared toward work that changes the conversation in the field: proposals are expected to introduce genuinely new ideas, challenge existing assumptions, or approach persistent problems from fresh angles rather than offering small, incremental extensions of already published findings.

A central expectation is that applicants clearly explain why the proposed work matters both in the near term and long term. This includes describing the anticipated short- and long-range impact of the research and presenting an evidence-based discussion of the public health burden associated with Lyme disease and/or other tick-borne diseases. Competitive applications are expected to be built around a well-formed, testable hypothesis grounded in strong scientific reasoning. That rationale should be demonstrated through a thoughtful analysis of existing literature and may be strengthened by preliminary data when available, though the mechanism is framed to support idea development and proof-of-principle work rather than requiring mature, late-stage evidence.

In terms of scientific scope, the award supports a wide range of research along the basic-to-translational continuum. This includes basic mechanistic studies, preclinical work, and clinical research approaches that do not meet the definition of a clinical trial. Correlative studies linked to an existing clinical trial are allowed when they help establish proof-of-principle and set the stage for future development, but the program does not permit applicants to run clinical trials under this announcement. Here, a clinical trial is specifically defined as a study where human participants are prospectively assigned to one or more interventions (including placebo or control conditions) to evaluate effects on biomedical or behavioral health outcomes. Human subjects research and the use of human anatomical substances are permitted, as long as the work does not cross into a prohibited clinical trial design.

The program strongly encourages investigators to take advantage of existing resources to strengthen study validity and statistical power. While not mandatory, applicants are encouraged to use validated specimens and data from established Lyme and tick-borne disease biorepositories and databases. If curated biospecimens or datasets are used, the proposal should clearly explain the inclusion and exclusion criteria that governed how those materials were selected and maintained, so reviewers can judge whether the resources are appropriate and the conclusions will be reliable. The announcement also pushes for rigorous research practices, including authentication of cell lines when relevant, strong statistical rigor for in vitro and animal studies, and validation in well-characterized patient cohorts with consistent clinical documentation. Projects that leverage large patient datasets with long-term health records and associated biospecimen collections are viewed favorably, especially when paired with modern analytic approaches such as genomics, proteomics, advanced bioinformatics, or mathematical modeling.

From a funding and award structure standpoint, the Department of Defense will issue this support as an assistance agreement, meaning the government is providing resources to advance a public-purpose research goal rather than purchasing goods or services for direct government use. Awards may be made either as grants or cooperative agreements. The deciding factor is how much involvement the DoD expects to have during the project period. If no substantial federal involvement is anticipated, the result is typically a grant; if substantial involvement is expected (for example, collaboration or active participation by the funder during execution), the award will be a cooperative agreement and will spell out the nature of that involvement. The exact award type and project start date are determined during negotiations.

Financially, the anticipated cap for direct costs over the entire period of performance is up to $600,000 per award. Program-wide, the CDMRP planned to allocate about $4.8 million total to make roughly five Idea Development Awards, with actual funding dependent on federal fund availability, the number of submissions, and the scientific and programmatic merit determined through review. The original application closing date listed for this FY21 opportunity was August 27, 2021, and awards were expected to be made no later than September 30, 2022. The funding is tied to FY21 appropriations, with the associated funds available for use for a limited period and expected to expire for use on September 30, 2027.

In short, this opportunity is best suited for research teams proposing bold, hypothesis-driven projects with a clear path to proof-of-principle and future development, backed by rigorous study design and a convincing case that the work could substantially advance understanding, diagnosis, prevention, or management of Lyme disease and other tick-borne diseases, particularly in ways that matter to military-connected populations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Tick-Borne Disease, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 22, 2021.
• Applicants must submit their applications by Aug 27, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 TBDRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: